| Symbol
| CDKL3
| contributors: mct/npt - updated : 20-12-2021
|
| HGNC name
| cyclin-dependent kinase-like 3
|
| HGNC id
| 15483
|
| Other morbid association(s)
|
| Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
|---|
| constitutional
|
|
|
| loss of function
| |
in mental retardation | | tumoral
|
| deletion
|
|
| |
in dysmyelopoiesis | | tumoral
|
|
| --over
|
|
in esophageal squamous cell carcinoma ESCC) with poor prognosis  | |
Variant & Polymorphism
| 
| |
Candidate gene
| Marker
| biomarker for Osteosarcoma (OS) prognosis ( | Therapy target
|
|
| System | Type | Disorder | Pubmed |
|---|
| cancer | bone | | |
| potential therapeutic target to treat AKT1 hyper-activated Osteosarcoma (OS) | | cancer | digestive | oesophagus | |
| may be as a new therapeutic target in ESCC | | cancer | brain | glioma/neuroblstoma | |
| CDKL3 as a promising therapeutic target of glioma |
| | |